Inflammation and immunity in diabetic vascular complications

Purpose of review Diabetes is associated with an increased risk for cardiovascular disease. The purpose of this review is to discuss possible mechanisms through which diabetes can contribute to a more aggressive atherosclerotic disease process with a particular focus on the role of innate and adaptive immunity. Recent findings The observation that adaptive immune responses to oxidized LDL modulate atherosclerotic plaque development has led to development of pilot vaccines that inhibit atherosclerosis in experimental animals. Recent studies have shown that similar immune responses operate against self-antigens modified by glycation in diabetes. Diabetes has also been shown to activate proinflammatory innate immune receptors and intracellular oxidative stress. Summary There are many similarities between the autoimmune responses against oxidized LDL and proteins modified by glycation. The role of autoimmune responses against modified self-antigens in the development of diabetic vascular complications represents a relatively unexplored concept that potentially could provide significant new mechanistic insight into the underlying disease process and identify novel targets for intervention.

[1]  P. Libby,et al.  Genetically programmed biases in Th1 and Th2 immune responses modulate atherogenesis. , 2008, The American journal of pathology.

[2]  H. Björkbacka,et al.  Nanomolar concentrations of lysophosphatidylcholine recruit monocytes and induce pro-inflammatory cytokine production in macrophages. , 2008, Biochemical and biophysical research communications.

[3]  G. Hansson,et al.  Autoimmunity in atherosclerosis: a protective response losing control? , 2008, Journal of internal medicine.

[4]  G. Gurtner,et al.  Decreasing Intracellular Superoxide Corrects Defective Ischemia-induced New Vessel Formation in Diabetic Mice* , 2008, Journal of Biological Chemistry.

[5]  S. Griffen,et al.  Increased Toll-like Receptor (tlr) 2 and Tlr4 Expression in Monocytes from Patients with Type 1 Diabetes: Further , 2022 .

[6]  P. Shah,et al.  Recombinant antibodies to an oxidized low-density lipoprotein epitope induce rapid regression of atherosclerosis in apobec-1(-/-)/low-density lipoprotein receptor(-/-) mice. , 2007, Journal of the American College of Cardiology.

[7]  Kun Wook Chung,et al.  Toll-like receptor 2 senses beta-cell death and contributes to the initiation of autoimmune diabetes. , 2007, Immunity.

[8]  T. Hawn,et al.  Toll-Like Receptor-4 Mediates Vascular Inflammation and Insulin Resistance in Diet-Induced Obesity , 2007, Circulation research.

[9]  W. Hsueh,et al.  Recipes for creating animal models of diabetic cardiovascular disease. , 2007, Circulation research.

[10]  J. Tanti,et al.  C3H/HeJ mice carrying a toll-like receptor 4 mutation are protected against the development of insulin resistance in white adipose tissue in response to a high-fat diet , 2007, Diabetologia.

[11]  K. Bornfeldt,et al.  Do Glucose and Lipids Exert Independent Effects on Atherosclerotic Lesion Initiation or Progression to Advanced Plaques? , 2007, Circulation research.

[12]  J. Flier,et al.  TLR4 links innate immunity and fatty acid-induced insulin resistance. , 2006, The Journal of clinical investigation.

[13]  I. Goldberg,et al.  Diabetic Vascular Disease: An Experimental Objective , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[14]  Marnie L. Gruen,et al.  Plasma insulin levels predict atherosclerotic lesion burden in obese hyperlipidemic mice. , 2006, Atherosclerosis.

[15]  J. Molkentin,et al.  High Glucose Activates Nuclear Factor of Activated T Cells in Native Vascular Smooth Muscle , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[16]  P. Shah,et al.  Immunomodulation of atherosclerosis with a vaccine , 2005, Nature Clinical Practice Cardiovascular Medicine.

[17]  P. Tobias,et al.  Modulation of atherosclerosis in mice by Toll-like receptor 2. , 2005, The Journal of clinical investigation.

[18]  J. Ge,et al.  Advanced Glycosylation End Products Might Promote Atherosclerosis Through Inducing the Immune Maturation of Dendritic Cells , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[19]  M. Cooper,et al.  Rosiglitazone Attenuates Atherosclerosis in a Model of Insulin Insufficiency Independent of Its Metabolic Effects , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[20]  L. Mitnaul,et al.  Increased hypercholesterolemia and atherosclerosis in mice lacking both ApoE and leptin receptor. , 2005, Atherosclerosis.

[21]  K. Moore,et al.  Loss of receptor-mediated lipid uptake via scavenger receptor A or CD36 pathways does not ameliorate atherosclerosis in hyperlipidemic mice. , 2005, The Journal of clinical investigation.

[22]  Michael Brownlee,et al.  The pathobiology of diabetic complications: a unifying mechanism. , 2005, Diabetes.

[23]  H. Methe,et al.  Expansion of Circulating Toll-Like Receptor 4–Positive Monocytes in Patients With Acute Coronary Syndrome , 2005, Circulation.

[24]  G. Berglund,et al.  Association between diet, lifestyle, metabolic cardiovascular risk factors, and plasma C-reactive protein levels. , 2004, Metabolism: clinical and experimental.

[25]  Jan Nilsson,et al.  Recombinant Human Antibodies Against Aldehyde-Modified Apolipoprotein B-100 Peptide Sequences Inhibit Atherosclerosis , 2004, Circulation.

[26]  E. Fisher,et al.  Dyslipidemia associated with atherosclerotic disease systemically alters dendritic cell mobilization. , 2004, Immunity.

[27]  I. Goldberg.  Why does diabetes increase atherosclerosis? I don't know! , 2004, The Journal of clinical investigation.

[28]  A. Chait,et al.  Diabetes and diabetes-associated lipid abnormalities have distinct effects on initiation and progression of atherosclerotic lesions. , 2004, The Journal of clinical investigation.

[29]  S. Akira,et al.  Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[30]  R. Krauss.  Lipids and lipoproteins in patients with type 2 diabetes. , 2004, Diabetes care.

[31]  K. Moore,et al.  Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways , 2004, Nature Medicine.

[32]  Nancy R Cook,et al.  C-Reactive Protein, the Metabolic Syndrome, and Risk of Incident Cardiovascular Events: An 8-Year Follow-Up of 14 719 Initially Healthy American Women , 2003, Circulation.

[33]  J. Witztum,et al.  Innate and acquired immunity in atherogenesis , 2002, Nature Medicine.

[34]  Peter Libby,et al.  Innate and Adaptive Immunity in the Pathogenesis of Atherosclerosis , 2002, Circulation research.

[35]  Peter Libby,et al.  Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. , 2002, JAMA.

[36]  D. Singer,et al.  The effect of interventions to prevent cardiovascular disease in patients with type 2 diabetes mellitus. , 2001, The American journal of medicine.

[37]  Christopher K. Glass,et al.  Atherosclerosis The Road Ahead , 2001, Cell.

[38]  N. Turk,et al.  Detection of autoantibodies against advanced glycation endproducts and AGE-immune complexes in serum of patients with diabetes mellitus. , 2001, Clinica chimica acta; international journal of clinical chemistry.

[39]  Xinghua Zhou,et al.  Transfer of CD4+ T Cells Aggravates Atherosclerosis in Immunodeficient Apolipoprotein E Knockout Mice , 2000, Circulation.

[40]  G. Bellomo,et al.  Antibodies against advanced glycation end product Nɛ-(carboxymethyl)lysine in healthy controls and diabetic patients , 2000, Diabetologia.

[41]  G. Silverman,et al.  Immunological responses to oxidized LDL. , 2000, Free radical biology & medicine.

[42]  S. Hazen,et al.  Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. , 2000, The Journal of clinical investigation.

[43]  C. Anderson,et al.  Predictors of death and vascular events in the elderly : the Perth Community Stroke Study. , 2000, Stroke.

[44]  J. Witztum,et al.  Immune responses to oxidative neoepitopes on LDL and phospholipids modulate the development of atherosclerosis , 2000, Journal of internal medicine.

[45]  Teven,et al.  MORTALITY FROM CORONARY HEART DISEASE IN SUBJECTS WITH TYPE 2 DIABETES AND IN NONDIABETIC SUBJECTS WITH AND WITHOUT PRIOR MYOCARDIAL INFARCTION , 2000 .

[46]  Paul J Thornalley,et al.  Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. , 1999, The Biochemical journal.

[47]  H. Hammes,et al.  Diabetic retinopathy risk correlates with intracellular concentrations of the glycoxidation product Ne-(carboxymethyl) lysine independently of glycohaemoglobin concentrations , 1999, Diabetologia.

[48]  S. Horiuchi,et al.  Immunohistochemical localization of different epitopes of advanced glycation end products in human atherosclerotic lesions. , 1998, Atherosclerosis.

[49]  A. Schmidt,et al.  Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts , 1998, Nature Medicine.

[50]  A. Hamsten,et al.  Evidence for a role of tumor necrosis factor alpha in disturbances of triglyceride and glucose metabolism predisposing to coronary heart disease. , 1998, Metabolism: clinical and experimental.

[51]  Yukiko Kurihara,et al.  A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection , 1997, Nature.

[52]  P. Shah,et al.  Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[53]  L. L. Moore,et al.  Formation of Immunochemical Advanced Glycosylation End Products Precedes and Correlates With Early Manifestations of Renal and Retinal Disease in Diabetes , 1995, Diabetes.

[54]  Clark Cm,et al.  Prevention and Treatment of the Complications of Diabetes Mellitus , 1995 .

[55]  P. Edwards,et al.  Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. , 1995, Circulation.

[56]  E. Miller,et al.  Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[57]  C. Clark,et al.  Prevention and treatment of the complications of diabetes mellitus. , 1995, The New England journal of medicine.

[58]  V. Meiner,et al.  Frameshift and splice-junction mutations in the sterol 27-hydroxylase gene cause cerebrotendinous xanthomatosis in Jews or Moroccan origin. , 1993, The Journal of clinical investigation.

[59]  Y. Morino,et al.  Immunochemical evidence for the presence of advanced glycation end products in human lens proteins and its positive correlation with aging. , 1992, The Journal of biological chemistry.

[60]  G. Gabbiani,et al.  Expression of class II transplantation antigen on vascular smooth muscle cells in human atherosclerosis. , 1985, The Journal of clinical investigation.